Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016 (2016), Article ID 7629724, 16 pages
http://dx.doi.org/10.1155/2016/7629724
Review Article

Clinical Advancements in the Targeted Therapies against Liver Fibrosis

Targeted Therapeutics, Department of Biomaterials Science and Technology, Faculty of Science and Technology, University of Twente, Enschede, Netherlands

Received 13 June 2016; Revised 11 October 2016; Accepted 19 October 2016

Academic Editor: Mirella Giovarelli

Copyright © 2016 Ruchi Bansal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. S. Samuel, E. D. Lekgabe, and I. Mookerjee, “The effects of relaxin on extracellular matrix remodeling in health and fibrotic disease,” in Relaxin and Related Peptides, A. Agoulnik, Ed., vol. 612 of Advances in Experimental Medicine and Biology, pp. 88–103, Springer, New York, NY, USA, 2007. View at Publisher · View at Google Scholar
  2. R. Bataller and D. A. Brenner, “Liver fibrosis,” Journal of Clinical Investigation, vol. 115, no. 2, pp. 209–218, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. O. A. Gressner, R. Weiskirchen, and A. M. Gressner, “Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options,” Comparative Hepatology, vol. 6, article 7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Bedossa and F. Carrat, “Liver biopsy: the best, not the gold standard,” Journal of Hepatology, vol. 50, no. 1, pp. 1–3, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Regev, M. Berho, L. J. Jeffers et al., “Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection,” The American Journal of Gastroenterology, vol. 97, no. 10, pp. 2614–2618, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. D. C. Rockey, S. H. Caldwell, Z. D. Goodman, R. C. Nelson, and A. D. Smith, “Liver biopsy,” Hepatology, vol. 49, no. 3, pp. 1017–1044, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Bedossa, D. Dargère, and V. Paradis, “Sampling variability of liver fibrosis in chronic hepatitis C,” Hepatology, vol. 38, no. 6, pp. 1449–1457, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. European Association for the Study of the Liver and Asociacion Latinoamericana para el Estudio del Higado, “EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis,” Journal of Hepatology, vol. 63, no. 1, pp. 237–264, 2015. View at Publisher · View at Google Scholar
  9. J. Boursier, Y. Bacq, P. Halfon et al., “Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C,” European Journal of Gastroenterology and Hepatology, vol. 21, no. 1, pp. 28–38, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Calès, J. Boursier, F. Oberti et al., “FibroMeters: a family of blood tests for liver fibrosis with high diagnostic performance and applicability in clinical practice,” Pathologie Biologie, vol. 57, no. 6, pp. 459–462, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Lichtinghagen, D. Pietsch, H. Bantel, M. P. Manns, K. Brand, and M. J. Bahr, “The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values,” Journal of Hepatology, vol. 59, no. 2, pp. 236–242, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Pohl, C. Behling, D. Oliver, M. Kilani, P. Monson, and T. Hassanein, “Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection,” American Journal of Gastroenterology, vol. 96, no. 11, pp. 3142–3146, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Vallet-Pichard, V. Mallet, B. Nalpas et al., “FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest,” Hepatology, vol. 46, no. 1, pp. 32–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. D. C. Rockey and D. M. Bissell, “Noninvasive measures of liver fibrosis,” Hepatology, vol. 43, no. 2, pp. S113–S120, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Castera, X. Forns, and A. Alberti, “Non-invasive evaluation of liver fibrosis using transient elastography,” Journal of Hepatology, vol. 48, no. 5, pp. 835–847, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Castera, “Is it really worth adapting liver stiffness cut-offs according to AST levels?” Liver International, vol. 35, no. 12, pp. 2495–2497, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. O. H. Orasan, M. Iancu, M. Sava et al., “Non-invasive assessment of liver fibrosis in chronic viral hepatitis,” European Journal of Clinical Investigation, vol. 45, no. 12, pp. 1243–1251, 2015. View at Publisher · View at Google Scholar
  18. M. Thiele, S. Detlefsen, L. Sevelsted Møller et al., “Transient and 2-dimensional shear-wave elastography provide comparable assessment of alcoholic liver fibrosis and cirrhosis,” Gastroenterology, vol. 150, no. 1, pp. 123–133, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Attia, H. Bantel, H. Lenzen, M. P. Manns, M. J. Gebel, and A. Potthoff, “Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients,” Alimentary Pharmacology & Therapeutics, vol. 44, no. 4, pp. 366–379, 2016. View at Publisher · View at Google Scholar
  20. M. Balakrishnan, F. Souza, C. Muñoz et al., “Liver and spleen stiffness measurements by point shear wave elastography via acoustic radiation force impulse: intraobserver and interobserver variability and predictors of variability in a US population,” Journal of Ultrasound in Medicine, vol. 35, no. 1, pp. 2373–2380, 2016. View at Publisher · View at Google Scholar
  21. N. Harris, D. Nadebaum, M. Christie et al., “Acoustic radiation force impulse accuracy and the impact of hepatic steatosis on liver fibrosis staging,” Journal of Medical Imaging and Radiation Oncology, vol. 60, no. 5, pp. 587–592, 2016. View at Publisher · View at Google Scholar
  22. E. Karagoz, C. Ozturker, and A. K. Sivrioglu, “Noninvasive evaluation of liver fibrosis: is acoustic radiation force impulse a useful tool for evaluating liver fibrosis in patients with chronic hepatitis B and C?” Journal of Ultrasound in Medicine, vol. 35, no. 3, p. 668, 2016. View at Google Scholar
  23. A. Kiani, V. Brun, F. Lainé et al., “Acoustic radiation force impulse imaging for assessing liver fibrosis in alcoholic liver disease,” World Journal of Gastroenterology, vol. 22, no. 20, pp. 4926–4935, 2016. View at Publisher · View at Google Scholar
  24. C. Ozturker, E. Karagoz, and M. Incedayi, “Non-invasive evaluation of liver fibrosis: 2-D shear wave elastography, transient elastography or acoustic radiation force impulse imaging?” Ultrasound in Medicine & Biology, vol. 42, no. 12, p. 3052, 2016. View at Publisher · View at Google Scholar
  25. Y. Tachi, T. Hirai, Y. Kojima et al., “Liver stiffness measurement using acoustic radiation force impulse elastography in hepatitis C virus-infected patients with a sustained virological response,” Alimentary Pharmacology & Therapeutics, vol. 44, no. 4, pp. 346–355, 2016. View at Publisher · View at Google Scholar
  26. M. Muller, J.-L. Gennisson, T. Deffieux, M. Tanter, and M. Fink, “Quantitative viscoelasticity mapping of human liver using supersonic shear imaging: preliminary in vivo feasability study,” Ultrasound in Medicine and Biology, vol. 35, no. 2, pp. 219–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Huwart and B. E. van Beers, “MR elastography,” Gastroenterologie Clinique et Biologique, vol. 32, no. 6, pp. 68–72, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Huwart, C. Sempoux, E. Vicaut et al., “Magnetic resonance elastography for the noninvasive staging of liver fibrosis,” Gastroenterology, vol. 135, no. 1, pp. 32–40, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Taouli and D.-M. Koh, “Diffusion-weighted MR imaging of the liver,” Radiology, vol. 254, no. 1, pp. 47–66, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Cui, E. Heba, C. Hernandez et al., “Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A Prospective Study,” Hepatology, vol. 63, no. 2, pp. 453–461, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Shi, F. Xia, Q. Li et al., “Magnetic resonance elastography for the evaluation of liver fibrosis in chronic hepatitis B and C by using both gradient-recalled echo and spin-echo echo planar imaging: A Prospective Study,” The American Journal of Gastroenterology, vol. 111, no. 6, pp. 823–833, 2016. View at Publisher · View at Google Scholar
  32. S. Singh, S. K. Venkatesh, R. Loomba et al., “Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis,” European Radiology, vol. 26, no. 5, pp. 1431–1440, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. C. H. Tan and S. K. Venkatesh, “Magnetic resonance elastography and other magnetic resonance imaging techniques in chronic liver disease: current status and future directions,” Gut and Liver, vol. 10, no. 5, pp. 672–686, 2016. View at Publisher · View at Google Scholar
  34. B. Taouli and L. Serfaty, “Magnetic resonance imaging/elastography is superior to transient elastography for detection of liver fibrosis and fat in nonalcoholic fatty liver disease,” Gastroenterology, vol. 150, no. 3, pp. 553–556, 2016. View at Publisher · View at Google Scholar
  35. D. Wolff, J. P. van Melle, H. Dijkstra et al., “The Fontan circulation and the liver: a magnetic resonance diffusion-weighted imaging study,” International Journal of Cardiology, vol. 202, pp. 595–600, 2016. View at Publisher · View at Google Scholar
  36. B. Chen, C. Hsu, C. Yu, P. Liang, A. Cheng, and T. T. Shih, “Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy,” Radiology, vol. 281, no. 2, pp. 454–464, 2016. View at Publisher · View at Google Scholar
  37. D. Feier, C. Balassy, N. Bastati, R. Fragner, F. Wrba, and A. Ba-Ssalamah, “The diagnostic efficacy of quantitative liver MR imaging with diffusion-weighted, SWI, and hepato-specific contrast-enhanced sequences in staging liver fibrosis—a multiparametric approach,” European Radiology, vol. 26, no. 2, pp. 539–546, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. T. D. Vreugdenburg, N. Ma, J. K. Duncan, D. Riitano, A. L. Cameron, and G. J. Maddern, “Comparative diagnostic accuracy of hepatocyte-specific gadoxetic acid (Gd-EOB-DTPA) enhanced MR imaging and contrast enhanced CT for the detection of liver metastases: a systematic review and meta-analysis,” International Journal of Colorectal Disease, vol. 31, no. 11, pp. 1739–1749, 2016. View at Publisher · View at Google Scholar
  39. C. T. Farrar, D. K. Deperalta, H. Day et al., “3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model,” Journal of Hepatology, vol. 63, no. 3, pp. 689–696, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Polasek, B. C. Fuchs, R. Uppal et al., “Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models,” Journal of Hepatology, vol. 57, no. 3, pp. 549–555, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. B. Powroźnik, P. Kubowicz, and E. Pękala, “Monoclonal antibodies in targeted therapy,” Postepy Higieny i Medycyny Doswiadczalnej, vol. 66, pp. 663–673, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Giaccone and J. C. Soria, Targeted Therapies in Oncology, CRC Press, Boca Raton, Fla, USA, 2007.
  43. H. Le Pabic, A. L'Helgoualc'h, A. Coutant et al., “Involvement of the serine/threonine p70S6 kinase in TGF-β1-induced ADAM12 expression in cultured human hepatic stellate cells,” Journal of Hepatology, vol. 43, no. 6, pp. 1038–1044, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. E. G. Huntzicker, Z. D. Goodman, R. Loomba et al., “Hepatic expression of the apoptosis signal-regulating kinase 1 (ASK1) marker, phosphorylated-P38 (p-P38), correlates with fibrosis stage in patients with NAFLD in poster session 4: steatohepatitis: clinical and therapeutic,” Hepatology, vol. 62, pp. 1252A–1305A, 2015. View at Google Scholar
  45. E. Patsenker, V. Schneider, M. Ledermann et al., “Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis,” Journal of Hepatology, vol. 55, no. 2, pp. 388–398, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Li, Y. Zhang, R. Kuruba et al., “Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells,” Molecular Pharmacology, vol. 80, no. 1, pp. 191–200, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. A. L. Nelson, E. Dhimolea, and J. M. Reichert, “Development trends for human monoclonal antibody therapeutics,” Nature Reviews Drug Discovery, vol. 9, no. 10, pp. 767–774, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Talal, M. Feron-Rigodon, J. Madere et al., “A monoclonal antibody directed at the Lysyl Oxidase-Like 2 (LOXL2) enzyme appears safe and well tolerated in patients with liver disease in AASLD abstracts,” Hepatology, vol. 56, no. 1, pp. 191A–1144A, 2012. View at Google Scholar
  49. R. Ganesh, M. B. Scholand, J. D. Andrade et al., “Safety and efficacy of anti-CTGF monoclonal antibody FG-3019 for treatment of idiopathic pulmonary fibrosis (IPF): results of phase 2 clinical trial two years after initiation,” in A38. Diamonds are Forever but New Treatments for Interstitial Lung Disease Can't Wait, p. A1426, American Thoracic Societ, 2014. View at Google Scholar
  50. R. Bansal, J. Prakash, E. Post, L. Beljaars, D. Schuppan, and K. Poelstra, “Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice,” Hepatology, vol. 54, no. 2, pp. 586–596, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Sato, K. Murase, J. Kato et al., “Resolution of liver cirrhosis using vitamin A—coupled liposomes to deliver siRNA against a collagen-specific chaperone,” Nature Biotechnology, vol. 26, no. 4, pp. 431–442, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. S.-L. Du, H. Pan, W.-Y. Lu, J. Wang, J. Wu, and J.-Y. Wang, “Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 2, pp. 560–568, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. N. J. Torok, J. A. Dranoff, D. Schuppan, and S. L. Friedman, “Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014,” Hepatology, vol. 62, no. 2, pp. 627–634, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Hoelder, P. A. Clarke, and P. Workman, “Discovery of small molecule cancer drugs: successes, challenges and opportunities,” Molecular Oncology, vol. 6, no. 2, pp. 155–176, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Xue, A. Gudkov, M. Haber, and M. D. Norris, Small Molecule Drugs and Targeted Therapies for Neuroblastoma, INTECH Open Access, Rijeka, Croatia, 2012.
  56. J. Mann and D. A. Mann, “Transcriptional regulation of hepatic stellate cells,” Advanced Drug Delivery Reviews, vol. 61, no. 7-8, pp. 497–512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. F. Marra, E. Efsen, R. G. Romanelli et al., “Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells,” Gastroenterology, vol. 119, no. 2, pp. 466–478, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Yang, C.-C. Chan, O.-S. Kwon et al., “Regulation of peroxisome proliferator-activated receptor-γ in liver fibrosis,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 291, no. 5, pp. G902–G911, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. A. J. Sanyal, “ACP Journal Club: vitamin E, but not pioglitazone, improved nonalcoholic steatohepatitis in nondiabetic patients,” Annals of Internal Medicine, vol. 153, no. 6, p. JC3-12, 2010. View at Google Scholar
  60. A. J. Sanyal, N. Chalasani, K. V. Kowdley et al., “Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 362, no. 18, pp. 1675–1685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. J. McHutchison, Z. Goodman, K. Patel et al., “Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection,” Gastroenterology, vol. 138, no. 4, pp. 1365–1373.e2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. “Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects,” 2016, https://clinicaltrials.gov/show/NCT00244751.
  63. P. J. Trivedi, G. M. Hirschfield, and M. E. Gershwin, “Obeticholic acid for the treatment of primary biliary cirrhosis,” Expert Review of Clinical Pharmacology, vol. 9, no. 1, pp. 13–26, 2016. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Fiorucci, E. Antonelli, G. Rizzo et al., “The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis,” Gastroenterology, vol. 127, no. 5, pp. 1497–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Carotti, M. Marinozzi, C. Custodi et al., “Beyond bile acids: targeting farnesoid x receptor (fxr) with natural and synthetic ligands,” Current Topics in Medicinal Chemistry, vol. 14, no. 19, pp. 2129–2142, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. “Single Ascending Oral Dose Phase I Study With Px-102,” https://clinicaltrials.gov/show/NCT01998659.
  67. B. A. Neuschwander-Tetri, R. Loomba, A. J. Sanyal et al., “Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial,” The Lancet, vol. 385, no. 9972, pp. 956–965, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Yoshiji, S. Kuriyama, and H. Fukui, “Blockade of renin-angiotensin system in antifibrotic therapy,” Journal of Gastroenterology and Hepatology, vol. 22, supplement 1, pp. S93–S95, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Y. Kim, S. K. Baik, D. H. Park et al., “Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model,” Journal of Gastroenterology, vol. 43, no. 11, pp. 889–896, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. R. Bataller, P. Ginès, J. M. Nicolás et al., “Angiotensin II induces contraction and proliferation of human hepatic stellate cells,” Gastroenterology, vol. 118, no. 6, pp. 1149–1156, 2000. View at Publisher · View at Google Scholar · View at Scopus
  71. M. G. Ghany, D. E. Kleiner, H. Alter et al., “Progression of fibrosis in chronic hepatitis C,” Gastroenterology, vol. 124, no. 1, pp. 97–104, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. P. Cales, Y. Bacq, J. P. Vinel et al., “Irbesartan for severe fibrosis in chronic hepatitis C: a double-blind randomized trial (ANRS HC19 Fibrosar),” Hepatology, vol. 60, no. 4, supplement, article 423A, 2014. View at Google Scholar
  73. P. Charatcharoenwitthaya, J. A. Talwalkar, P. Angulo et al., “Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid,” Digestive Diseases and Sciences, vol. 55, no. 2, pp. 476–483, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Colmenero, R. Bataller, P. Sancho-Bru et al., “Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 297, no. 4, pp. G726–G734, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Y. Kim, M. Y. Cho, S. K. Baik et al., “Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis‐a randomized open‐label controlled study,” Liver International, vol. 32, no. 6, pp. 977–987, 2012. View at Publisher · View at Google Scholar
  76. B. K. Abu Dayyeh, M. Yang, J. L. Dienstag, and R. T. Chung, “The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort,” Digestive Diseases and Sciences, vol. 56, no. 2, pp. 564–568, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. P. P. Basu, M. M. Aloysius, N. J. Shah, and R. S. Brown Jr., “Review article: the endocannabinoid system in liver disease, a potential therapeutic target,” Alimentary Pharmacology and Therapeutics, vol. 39, no. 8, pp. 790–801, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Tam, J. Liu, B. Mukhopadhyay, R. Cinar, G. Godlewski, and G. Kunos, “Endocannabinoids in liver disease,” Hepatology, vol. 53, no. 1, pp. 346–355, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Hézode, E. S. Zafrani, F. Roudot-Thoraval et al., “Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C,” Gastroenterology, vol. 134, no. 2, pp. 432–439, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. J. E. J. Boesten, J. Kaper, H. E. J. H. Stoffers, A. A. Kroon, and O. C. P. Van schayck, “Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (Cardiometabolic Risk Reduction by Rimonabant: the effectiveness in daily practice and its USE),” Family Practice, vol. 29, no. 5, pp. 521–527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. M. R. Ebrahimkhani, S. Kiani, F. Oakley et al., “Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats,” Gut, vol. 55, no. 11, pp. 1606–1616, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. R. G. Ruddell, F. Oakley, Z. Hussain et al., “A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis,” American Journal of Pathology, vol. 169, no. 3, pp. 861–876, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. E. Albanis and S. L. Friedman, “Hepatic fibrosis. Pathogenesis and principles of therapy,” Clinics in Liver Disease, vol. 5, no. 2, pp. 315–334, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Vircheva, A. Alexandrova, A. Georgieva et al., “In vivo effects of pentoxifylline on enzyme and non-enzyme antioxidant levels in rat liver after carrageenan-induced paw inflammation,” Cell Biochemistry and Function, vol. 28, no. 8, pp. 668–672, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Sherman, “Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis,” Seminars in Liver Disease, vol. 30, no. 1, pp. 3–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. X. W. Wang, N. H. H. Heegaard, and H. Orum, “MicroRNAs in liver disease,” Gastroenterology, vol. 142, no. 7, pp. 1431–1443, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Hoshino, B. Costa-Silva, T.-L. Shen et al., “Tumour exosome integrins determine organotropic metastasis,” Nature, vol. 527, no. 7578, pp. 329–335, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. W. Stoorvogel, “Functional transfer of microRNA by exosomes,” Blood, vol. 119, no. 3, pp. 646–648, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. C. O. Zein, L. M. Yerian, P. Gogate et al., “Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial,” Hepatology, vol. 54, no. 5, pp. 1610–1619, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. K. R. Karlmark, R. Weiskirchen, H. W. Zimmermann et al., “Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis,” Hepatology, vol. 50, no. 1, pp. 261–274, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. E. Seki, S. De Minicis, G.-Y. Gwak et al., “CCR1 and CCR5 promote hepatic fibrosis in mice,” The Journal of Clinical Investigation, vol. 119, no. 7, pp. 1858–1870, 2009. View at Google Scholar · View at Scopus
  92. E. Seki, S. De Minicis, S. Inokuchi et al., “CCR2 promotes hepatic fibrosis in mice,” Hepatology, vol. 50, no. 1, pp. 185–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Thompson, M. Saag, E. DeJesus et al., “A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus,” AIDS, vol. 30, no. 6, pp. 869–878, 2016. View at Publisher · View at Google Scholar
  94. E. Lefebvre, M. Gottwald, K. Lasseter et al., “Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment,” Clinical And Translational Science, vol. 9, no. 3, pp. 139–148, 2016. View at Publisher · View at Google Scholar
  95. N. C. Henderson, A. C. Mackinnon, S. L. Farnworth et al., “Galectin-3 regulates myofibroblast activation and hepatic fibrosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 13, pp. 5060–5065, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. E. Zomer, P. G. Traber, A. A. Klyosov, and E. Chekhova, Composition of Novel Carbohydrate Drug for Treatment of Human Diseases, World Intellectual Property Organization, 2013.
  97. P. G. Traber, H. Chou, E. Zomer et al., “Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease,” PLoS ONE, vol. 8, no. 10, Article ID e75361, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. R. O. Hynes, J. C. Lively, J. H. Mccarty et al., “The diverse roles of integrins and their ligands in angiogenesis,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 67, pp. 143–153, 2002. View at Publisher · View at Google Scholar
  99. S. Fiorucci, E. Antonelli, G. Rizzo et al., “The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis,” Gastroenterology, vol. 127, no. 5, pp. 1497–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. S. A. Harrison, N. P. Chalasani, E. Lawitz et al., “Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis,” The Liver Meeting 2014 Presentation, 2014. View at Google Scholar
  101. S. A. Harrison, N. P. Chalasani, E. Lawitz et al., “Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis in Parallel 8: novel approaches in diagnosis and treatment in NAFLD and NASH,” Hepatology, vol. 60, pp. 224A–227A, 2014. View at Google Scholar
  102. P. G. Traber, “Successful phase 1 clinical trial supports phase 2 clinical development program,” 2016, http://perspectives.galectintherapeutics.com/successful-phase-1-clinical-trial-supports-phase-2-clinical-development-program/.
  103. S. Barrientos, O. Stojadinovic, M. S. Golinko, H. Brem, and M. Tomic-Canic, “Growth factors and cytokines in wound healing,” Wound Repair and Regeneration, vol. 16, no. 5, pp. 585–601, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. S. L. Friedman, “Preface. Hepatic fibrosis: pathogenesis, diagnosis, and emerging therapies,” Clinical Liver Disease, vol. 12, no. 4, pp. 13–14, 2008. View at Publisher · View at Google Scholar
  105. S. L. Friedman, “Hepatic fibrosis-overview,” Toxicology, vol. 254, no. 3, pp. 120–129, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. K. Qu, Z. Huang, T. Lin et al., “New insight into the anti-liver fibrosis effect of multitargeted tyrosine kinase inhibitors: from molecular target to clinical trials,” Frontiers in Pharmacology, vol. 6, article 300, 2016. View at Publisher · View at Google Scholar
  107. M. Mejias, E. Garci-Pras, C. Tiani, R. Miquel, J. Bosch, and M. Fernandez, “Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats,” Hepatology, vol. 49, no. 4, pp. 1245–1256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Pinter, W. Sieghart, T. Reiberger, N. Rohr-Udilova, A. Ferlitsch, and M. Peck-Radosavljevic, “The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma—a pilot study,” Alimentary Pharmacology and Therapeutics, vol. 35, no. 1, pp. 83–91, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. B. C. Fuchs, Y. Hoshida, T. Fujii et al., “Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma,” Hepatology, vol. 59, no. 4, pp. 1577–1590, 2014. View at Publisher · View at Google Scholar · View at Scopus
  110. S. Carracedo, N. Lu, S. N. Popova, R. Jonsson, B. Eckes, and D. Gullberg, “The fibroblast integrin α11β1 is induced in a mechanosensitive manner involving activin A and regulates myofibroblast differentiation,” The Journal of Biological Chemistry, vol. 285, no. 14, pp. 10434–10445, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. J. H. Lin, J. J. Zhang, S.-L. Lin, and G. M. Chertow, “Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease,” Nephron, vol. 129, no. 1, pp. 29–33, 2015. View at Publisher · View at Google Scholar · View at Scopus
  112. S. Karnik, M. R. Charlton, L. Li et al., “Efficacy of an ASK1 inhibitor to reduce fibrosis and steatosis in a murine model of NASH is associated with normalization of lipids and hepatic gene expression and a reduction in serum biomarkers of inflammation and fibrosis in poster session 3: basic fibrosis research,” Hepatology, vol. 62, pp. 874A–903A, 2015. View at Google Scholar
  113. N. Hay and N. Sonenberg, “Upstream and downstream of mTOR,” Genes and Development, vol. 18, no. 16, pp. 1926–1945, 2004. View at Publisher · View at Google Scholar · View at Scopus
  114. R. A. Rahimi, M. Andrianifahanana, M. C. Wilkes et al., “Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-β,” Cancer Research, vol. 69, no. 1, pp. 84–93, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Sofroniadou and D. Goldsmith, “Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects,” Drug Safety, vol. 34, no. 2, pp. 97–115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. A. Desmoulière, I. A. Darby, and G. Gabbiani, “Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis,” Laboratory Investigation, vol. 83, no. 12, pp. 1689–1707, 2003. View at Publisher · View at Google Scholar · View at Scopus
  117. G. Gabbiani, “The myofibroblast in wound healing and fibrocontractive diseases,” Journal of Pathology, vol. 200, no. 4, pp. 500–503, 2003. View at Publisher · View at Google Scholar · View at Scopus
  118. D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer,” The New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  119. S. N. Popova, B. Rodriguez-Sánchez, Å. Lidén, C. Betsholtz, T. Van Den Bos, and D. Gullberg, “The mesenchymal α11β1 integrin attenuates PDGF-BB-stimulated chemotaxis of embryonic fibroblasts on collagens,” Developmental Biology, vol. 270, no. 2, pp. 427–442, 2004. View at Publisher · View at Google Scholar · View at Scopus
  120. C. J. Weston, E. L. Shepherd, L. C. Claridge et al., “Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis,” The Journal of Clinical Investigation, vol. 125, no. 2, pp. 501–520, 2015. View at Publisher · View at Google Scholar
  121. A. Autio, P. J. Vainio, S. Suilamo et al., “Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation,” Journal of Nuclear Medicine, vol. 54, no. 8, pp. 1315–1319, 2013. View at Google Scholar
  122. A. H. Ali, E. J. Carey, and K. D. Lindor, “Current research on the treatment of primary sclerosing cholangitis,” Intractable & Rare Diseases Research, vol. 4, no. 1, pp. 1–6, 2015. View at Publisher · View at Google Scholar
  123. W. Wang, X. Zhao, H. Hu et al., “Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetability,” Drug Delivery, vol. 17, no. 3, pp. 114–122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. A. K. Mandal, S. Das, M. K. Basu, R. N. Chakrabarti, and N. Das, “Hepatoprotective activity of liposomal flavonoid against arsenite-induced liver fibrosis,” Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 3, pp. 994–1001, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. N. Jiang, X. Zhang, X. Zheng et al., “Targeted gene silencing of TLR4 using liposomal nanoparticles for preventing liver ischemia reperfusion injury,” American Journal of Transplantation, vol. 11, no. 9, pp. 1835–1844, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. R. Greupink, H. I. Bakker, W. Bouma et al., “The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo,” Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 2, pp. 514–521, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. T. Gonzalo, E. G. Talman, A. Van De Ven et al., “Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology,” Journal of Controlled Release, vol. 111, no. 1-2, pp. 193–203, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. W. I. Hagens, A. Mattos, R. Greupink et al., “Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated,” Pharmaceutical Research, vol. 24, no. 3, pp. 566–574, 2007. View at Publisher · View at Google Scholar · View at Scopus
  129. W. I. Hagens, L. Beljaars, D. A. Mann et al., “Cellular targeting of the apoptosis-inducing compound gliotoxin to fibrotic rat livers,” Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 3, pp. 902–910, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. M. M. van Beuge, J. Prakash, M. Lacombe et al., “Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 337, no. 3, pp. 628–635, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. M. M. van Beuge, J. Prakash, M. Lacombe et al., “Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632,” Pharmaceutical Research, vol. 28, no. 8, pp. 2045–2054, 2011. View at Publisher · View at Google Scholar · View at Scopus
  132. S. Klein, M. M. Van Beuge, M. Granzow et al., “HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects,” Journal of Hepatology, vol. 57, no. 6, pp. 1220–1227, 2012. View at Publisher · View at Google Scholar · View at Scopus
  133. M. M. van Beuge, J. Prakash, M. Lacombe et al., “Enhanced effectivity of an ALK5-inhibitor after cell-specific delivery to hepatic stellate cells in mice with liver injury,” PLoS ONE, vol. 8, no. 2, Article ID e56442, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. Z. Zhang, C. Wang, Y. Zha et al., “Corona-directed nucleic acid delivery into hepatic stellate cells for liver fibrosis therapy,” ACS Nano, vol. 9, no. 3, pp. 2405–2419, 2015. View at Publisher · View at Google Scholar · View at Scopus
  135. R. Bansal, J. Prakash, M. D. Ruijter, L. Beljaars, and K. Poelstra, “Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis,” Molecular Pharmaceutics, vol. 8, no. 5, pp. 1899–1909, 2011. View at Publisher · View at Google Scholar · View at Scopus
  136. F. Li, Q.-H. Li, J.-Y. Wang, C.-Y. Zhan, C. Xie, and W.-Y. Lu, “Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor-beta on hepatic fibrosis in rats,” Journal of Controlled Release, vol. 159, no. 2, pp. 261–270, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. J. Yang, Y. Hou, G. Ji et al., “Targeted delivery of the RGD-labeled biodegradable polymersomes loaded with the hydrophilic drug oxymatrine on cultured hepatic stellate cells and liver fibrosis in rats,” European Journal of Pharmaceutical Sciences, vol. 52, no. 1, pp. 180–190, 2014. View at Publisher · View at Google Scholar · View at Scopus
  138. F. Li, J.-Y. Sun, J.-Y. Wang et al., “Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis,” Journal of Controlled Release, vol. 131, no. 1, pp. 77–82, 2008. View at Publisher · View at Google Scholar · View at Scopus
  139. W.-H. Kim, K. Matsumoto, K. Bessho, and T. Nakamura, “Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis,” The American Journal of Pathology, vol. 166, no. 4, pp. 1017–1028, 2005. View at Publisher · View at Google Scholar · View at Scopus
  140. C. He, L. Yin, C. Tang, and C. Yin, “Multifunctional polymeric nanoparticles for oral delivery of TNF-α siRNA to macrophages,” Biomaterials, vol. 34, no. 11, pp. 2843–2854, 2013. View at Publisher · View at Google Scholar · View at Scopus
  141. B. N. Melgert, P. Olinga, J. M. S. Van Der Laan et al., “Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats,” Hepatology, vol. 34, no. 4, part 1, pp. 719–728, 2001. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Bartneck, K. M. Scheyda, K. T. Warzecha et al., “Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases,” Biomaterials, vol. 37, pp. 367–382, 2015. View at Publisher · View at Google Scholar · View at Scopus
  143. T. Abel, E. El Filali, J. Waern et al., “Specific gene delivery to liver sinusoidal and artery endothelial cells,” Blood, vol. 122, no. 12, pp. 2030–2038, 2013. View at Publisher · View at Google Scholar · View at Scopus
  144. Y. Ohya, S. Takeda, Y. Shibata et al., “Evaluation of polyanion-coated biodegradable polymeric micelles as drug delivery vehicles,” Journal of Controlled Release, vol. 155, no. 1, pp. 104–110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  145. Z. Vadasz, O. Kessler, G. Akiri et al., “Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2,” Journal of Hepatology, vol. 43, no. 3, pp. 499–507, 2005. View at Publisher · View at Google Scholar · View at Scopus
  146. V. Barry-Hamilton, R. Spangler, D. Marshall et al., “Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment,” Nature Medicine, vol. 16, no. 9, pp. 1009–1017, 2010. View at Publisher · View at Google Scholar · View at Scopus
  147. H. M. Rodriguez, M. Vaysberg, A. Mikels et al., “Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor,” Journal of Biological Chemistry, vol. 285, no. 27, pp. 20964–20974, 2010. View at Publisher · View at Google Scholar · View at Scopus
  148. S. T. Jung, M. S. Kim, J. Y. Seo, H. C. Kim, and Y. Kim, “Purification of enzymatically active human lysyl oxidase and lysyl oxidase-like protein from Escherichia coli inclusion bodies,” Protein Expression and Purification, vol. 31, no. 2, pp. 240–246, 2003. View at Publisher · View at Google Scholar · View at Scopus
  149. S. K. Agarwal, “Integrins and cadherins as therapeutic targets in fibrosis,” Frontiers in Pharmacology, vol. 5, article 131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  150. N. Lu, S. Carracedo, J. Ranta, R. Heuchel, R. Soininen, and D. Gullberg, “The human α11 integrin promoter drives fibroblast-restricted expression in vivo and is regulated by TGF-β1 in a Smad- and Sp1-dependent manner,” Matrix Biology, vol. 29, no. 3, pp. 166–176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  151. W. Wang and M. Singh, Biological Drug Products: Development and Strategies, John Wiley & Sons, New York, NY, USA, 2013.
  152. C. Managit, S. Kawakami, F. Yamashita, and M. Hashida, “Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes,” Journal of Pharmaceutical Sciences, vol. 94, no. 10, pp. 2266–2275, 2005. View at Publisher · View at Google Scholar · View at Scopus
  153. S. Quan, Y. Wang, A. Zhou, P. Kumar, and R. Narain, “Galactose-based thermosensitive nanogels for targeted drug delivery of iodoazomycin arabinofuranoside (IAZA) for theranostic management of hypoxic hepatocellular carcinoma,” Biomacromolecules, vol. 16, no. 7, pp. 1978–1986, 2015. View at Publisher · View at Google Scholar · View at Scopus
  154. M. A. Hahn, A. K. Singh, P. Sharma, S. C. Brown, and B. M. Moudgil, “Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives,” Analytical and Bioanalytical Chemistry, vol. 399, no. 1, pp. 3–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  155. Z. Gao, A. M. Kennedy, D. A. Christensen, and N. Y. Rapoport, “Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy,” Ultrasonics, vol. 48, no. 4, pp. 260–270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  156. M. Bartneck, K. T. Warzecha, and F. Tacke, “Therapeutic targeting of liver inflammation and fibrosis by nanomedicine,” Hepatobiliary Surgery and Nutrition, vol. 3, no. 6, pp. 364–376, 2014. View at Google Scholar
  157. H. Sugimoto, T. M. Mundel, M. W. Kieran, and R. Kalluri, “Identification of fibroblast heterogeneity in the tumor microenvironment,” Cancer Biology and Therapy, vol. 5, no. 12, pp. 1640–1646, 2006. View at Publisher · View at Google Scholar · View at Scopus
  158. General Policies for Monoclonal Antibodies, World Health Organization, 2009.
  159. B. Hinz, S. H. Phan, V. J. Thannickal et al., “Recent developments in myofibroblast biology: paradigms for connective tissue remodeling,” The American Journal of Pathology, vol. 180, no. 4, pp. 1340–1355, 2012. View at Publisher · View at Google Scholar · View at Scopus
  160. J. J. Sauk, N. Nikitakis, and H. Siavash, “Hsp47 a novel collagen binding serpin chaperone, autoantigen and therapeutic target,” Frontiers in Bioscience, vol. 10, no. 2, pp. 107–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  161. E. Lawitz, Y. Tanaka, F. Poordad et al., “Safety, pharmacokinetics, and biologic activity of ND-L02-s0201, a novel targeted lipid-nanoparticle to deliver HSP47 siRNA for the treatment of patients with advanced liver fibrosis: interim results from clinical phase 1b/2 studies,” Hepatology, vol. 62, no. 1, supplement, 2015. View at Google Scholar